1. Home
  2. PRA vs NTLA Comparison

PRA vs NTLA Comparison

Compare PRA & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProAssurance Corporation

PRA

ProAssurance Corporation

HOLD

Current Price

$24.32

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$13.27

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRA
NTLA
Founded
1976
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.5B
IPO Year
2000
2016

Fundamental Metrics

Financial Performance
Metric
PRA
NTLA
Price
$24.32
$13.27
Analyst Decision
Hold
Buy
Analyst Count
2
20
Target Price
$25.00
$20.45
AVG Volume (30 Days)
705.7K
3.0M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.43
EPS
0.99
N/A
Revenue
$1,098,028,000.00
$67,671,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$62.75
P/E Ratio
$24.43
N/A
Revenue Growth
N/A
16.92
52 Week Low
$22.72
$5.97
52 Week High
$24.85
$28.24

Technical Indicators

Market Signals
Indicator
PRA
NTLA
Relative Strength Index (RSI) 40.86 52.90
Support Level $24.17 $12.55
Resistance Level $24.41 $14.32
Average True Range (ATR) 0.17 0.76
MACD -0.04 0.02
Stochastic Oscillator 29.05 73.43

Price Performance

Historical Comparison
PRA
NTLA

About PRA ProAssurance Corporation

ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: